{"id":44547,"date":"2015-03-12T09:17:17","date_gmt":"2015-03-12T08:17:17","guid":{"rendered":"http:\/\/www.r-biopharm.com\/?p=44547"},"modified":"2019-05-09T09:45:48","modified_gmt":"2019-05-09T07:45:48","slug":"drug-monitoring-der-biosimilars-remsima-und-inflectra","status":"publish","type":"post","link":"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/","title":{"rendered":"Medikamenten-Monitoring von Infliximab-Biosimilars"},"content":{"rendered":"
[vc_row][vc_column][vc_column_text css=“.vc_custom_1557387908662{margin-bottom: 0px !important;}“]Ann Gils und ihre Kollegen der KU Leuven untersuchten, ob die Biosimilars genauso gut wie der Originalwirkstoff Infliximab (IFX) in ihrem klinisch validierten Assay quantifiziert werden k\u00f6nnen.
\n<\/strong><\/p>\n

<\/p>\n

Die Forscher zeigten, dass der Assay identisch gegen\u00fcber den Biosimilars wie gegen\u00fcber dem Originalwirkstoff reagiert und sehr gut geeinet f\u00fcr das therapeutische Medikamenten-Monitoring (TDM) der Biosimilars ist.<\/p>\n

Der klinisch validierte Assay wurde in den CE-registrierten ELISA RIDASCREEN\u00ae IFX Monitoring<\/a> von R-Biopharm \u00fcberf\u00fchrt. F\u00fcr weitere Informationen zur Studie, lesen Sie das Abstract<\/a>.
\n<\/strong><\/p>\n

Relevanz von Medikamentenmonitoring<\/h3>\n

Mithilfe von therapeutischem Medikamenten-Monitoring\u00a0(TDM) k\u00f6nnen die Talspiegel-Konzentrationen im Blut eines Patienten \u00fcberpr\u00fcft werden. Das ist wichtig, da die Bioverf\u00fcgbarkeit von IFX wesentlich f\u00fcr seine Wirksamkeit\u00a0 ist. Medikamentenspiegel unterscheiden sich aufgrund individueller Pharmakokinetik. TDM hilft dabei, die Behandlung an die spezifischen Bed\u00fcrfnisse des Patienten anzupassen sowie die Behandlungskosten zu reduzieren.<\/p>\n

Mehr \u00fcber die Relevanz von Medikamenten-Monitoring von Infliximab erfahren Sie in der TAXIT-Studie<\/a>.<\/p>\n

Infliximab und seine Biosimilars
\n<\/strong><\/h3>\n

Infliximab (IFX) ist ein chim\u00e4rer Antik\u00f6rper, der gegen das pro-inflammatorische Zytokin TNF\u03b1 gerichtet ist und geh\u00f6rt zu den sogenannten TNF\u03b1-Blockern. Es wird f\u00fcr die Behandlung von entz\u00fcndlichen Erkrankungen wie Colitis ulcerosa und Morbus Crohn eingesetzt.[\/vc_column_text][vc_cta h2=“Fragen?“ shape=“square“ style=“flat“ add_button=“right“ btn_title=“Kontakt“ btn_style=“flat“ btn_shape=“square“ btn_color=“inverse“ btn_link=“url:mailto%3Aifx%40r-biopharm.de|||“]Interessiert an weiteren Informationen zum Thema therapeutisches Medikamentenmonitoring? Wir helfen Ihnen gern.[\/vc_cta][\/vc_column][\/vc_row]\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_column_text css=“.vc_custom_1557387908662{margin-bottom: 0px !important;}“]Ann Gils und ihre Kollegen der KU Leuven untersuchten, ob die Biosimilars genauso gut wie der Originalwirkstoff Infliximab (IFX) in ihrem klinisch validierten Assay quantifiziert werden k\u00f6nnen.<\/p>\n","protected":false},"author":324,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[255,239,252],"tags":[130,142,143,152,153],"class_list":["post-44547","post","type-post","status-publish","format-standard","hentry","category-elisa-de","category-gastroenterologie","category-therapeutisches-drug-monitoring","tag-drug-monitoring","tag-ifx","tag-inflectra","tag-remicade","tag-remsima"],"acf":[],"yoast_head":"\nMedikamenten-Monitoring von Infliximab-Biosimilars (de) - Clinical Diagnostics<\/title>\n<meta name=\"description\" content=\"Medikamenten-Monitoring von Remsima\u00ae und Inflectra\u00ae. RIDASCREEN\u00ae IFX Monitoring erkennt Biosimilars von Infliximab ebenso gut wie Remicade\u00ae.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medikamenten-Monitoring von Infliximab-Biosimilars (de) - Clinical Diagnostics\" \/>\n<meta property=\"og:description\" content=\"Medikamenten-Monitoring von Remsima\u00ae und Inflectra\u00ae. RIDASCREEN\u00ae IFX Monitoring erkennt Biosimilars von Infliximab ebenso gut wie Remicade\u00ae.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Diagnostics\" \/>\n<meta property=\"article:published_time\" content=\"2015-03-12T08:17:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-05-09T07:45:48+00:00\" \/>\n<meta name=\"author\" content=\"aschlereth\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"aschlereth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/\"},\"author\":{\"name\":\"aschlereth\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed\"},\"headline\":\"Medikamenten-Monitoring von Infliximab-Biosimilars\",\"datePublished\":\"2015-03-12T08:17:17+00:00\",\"dateModified\":\"2019-05-09T07:45:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/\"},\"wordCount\":268,\"keywords\":[\"drug monitoring\",\"IFX\",\"Inflectra\",\"Remicade\",\"Remsima\"],\"articleSection\":[\"ELISA\",\"Gastroenterologie\",\"Therapeutisches Drug Monitoring\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/\",\"url\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/\",\"name\":\"Medikamenten-Monitoring von Infliximab-Biosimilars (de) - Clinical Diagnostics\",\"isPartOf\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#website\"},\"datePublished\":\"2015-03-12T08:17:17+00:00\",\"dateModified\":\"2019-05-09T07:45:48+00:00\",\"author\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed\"},\"description\":\"Medikamenten-Monitoring von Remsima\u00ae und Inflectra\u00ae. RIDASCREEN\u00ae IFX Monitoring erkennt Biosimilars von Infliximab ebenso gut wie Remicade\u00ae.\",\"breadcrumb\":{\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/clinical.r-biopharm.com\/de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medikamenten-Monitoring von Infliximab-Biosimilars\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#website\",\"url\":\"https:\/\/clinical.r-biopharm.com\/fr\/\",\"name\":\"Clinical Diagnostics\",\"description\":\"A Division of the R-Biopharm Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/clinical.r-biopharm.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed\",\"name\":\"aschlereth\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2a8584ee89568ed5fc12875426a8801f1d5be5cef5a0cb5f54f1a866a4d2fb57?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2a8584ee89568ed5fc12875426a8801f1d5be5cef5a0cb5f54f1a866a4d2fb57?s=96&d=mm&r=g\",\"caption\":\"aschlereth\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medikamenten-Monitoring von Infliximab-Biosimilars (de) - Clinical Diagnostics","description":"Medikamenten-Monitoring von Remsima\u00ae und Inflectra\u00ae. RIDASCREEN\u00ae IFX Monitoring erkennt Biosimilars von Infliximab ebenso gut wie Remicade\u00ae.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/","og_locale":"de_DE","og_type":"article","og_title":"Medikamenten-Monitoring von Infliximab-Biosimilars (de) - Clinical Diagnostics","og_description":"Medikamenten-Monitoring von Remsima\u00ae und Inflectra\u00ae. RIDASCREEN\u00ae IFX Monitoring erkennt Biosimilars von Infliximab ebenso gut wie Remicade\u00ae.","og_url":"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/","og_site_name":"Clinical Diagnostics","article_published_time":"2015-03-12T08:17:17+00:00","article_modified_time":"2019-05-09T07:45:48+00:00","author":"aschlereth","twitter_misc":{"Verfasst von":"aschlereth","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/#article","isPartOf":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/"},"author":{"name":"aschlereth","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed"},"headline":"Medikamenten-Monitoring von Infliximab-Biosimilars","datePublished":"2015-03-12T08:17:17+00:00","dateModified":"2019-05-09T07:45:48+00:00","mainEntityOfPage":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/"},"wordCount":268,"keywords":["drug monitoring","IFX","Inflectra","Remicade","Remsima"],"articleSection":["ELISA","Gastroenterologie","Therapeutisches Drug Monitoring"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/","url":"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/","name":"Medikamenten-Monitoring von Infliximab-Biosimilars (de) - Clinical Diagnostics","isPartOf":{"@id":"https:\/\/clinical.r-biopharm.com\/fr\/#website"},"datePublished":"2015-03-12T08:17:17+00:00","dateModified":"2019-05-09T07:45:48+00:00","author":{"@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed"},"description":"Medikamenten-Monitoring von Remsima\u00ae und Inflectra\u00ae. RIDASCREEN\u00ae IFX Monitoring erkennt Biosimilars von Infliximab ebenso gut wie Remicade\u00ae.","breadcrumb":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/drug-monitoring-der-biosimilars-remsima-und-inflectra\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clinical.r-biopharm.com\/de\/"},{"@type":"ListItem","position":2,"name":"Medikamenten-Monitoring von Infliximab-Biosimilars"}]},{"@type":"WebSite","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#website","url":"https:\/\/clinical.r-biopharm.com\/fr\/","name":"Clinical Diagnostics","description":"A Division of the R-Biopharm Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clinical.r-biopharm.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed","name":"aschlereth","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2a8584ee89568ed5fc12875426a8801f1d5be5cef5a0cb5f54f1a866a4d2fb57?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2a8584ee89568ed5fc12875426a8801f1d5be5cef5a0cb5f54f1a866a4d2fb57?s=96&d=mm&r=g","caption":"aschlereth"}}]}},"_links":{"self":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/44547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/users\/324"}],"replies":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/comments?post=44547"}],"version-history":[{"count":4,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/44547\/revisions"}],"predecessor-version":[{"id":97058,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/44547\/revisions\/97058"}],"wp:attachment":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/media?parent=44547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/categories?post=44547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/tags?post=44547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}